| 73.29 -0.07 (-0.1%) | 10-15 12:16 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 88.95  |
1-year : | 91.73 |
| Resists | First : | 76.15 |
Second : | 78.54 |
| Pivot price | 75.62 |
|||
| Supports | First : | 72.3 | Second : | 60.15 |
| MAs | MA(5) : | 73.75 |
MA(20) : | 75.31 |
| MA(100) : | 77.37 |
MA(250) : | 73.96  |
|
| MACD | MACD : | -1.1 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 15.1 |
D(3) : | 17 |
| RSI | RSI(14): 34 |
|||
| 52-week | High : | 83 | Low : | 64.88 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ EW ] has closed above bottom band by 12.0%. Bollinger Bands are 8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 73.69 - 74.18 | 74.18 - 74.62 |
| Low: | 71.25 - 71.88 | 71.88 - 72.45 |
| Close: | 72.39 - 73.38 | 73.38 - 74.27 |
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Tue, 14 Oct 2025
Edwards Lifesciences: Inflection Incoming, But When? (NYSE:EW) - Seeking Alpha
Tue, 14 Oct 2025
How Edwards Lifesciences' (EW) Next-Gen Heart Valve Launch in Thailand Could Shape Its Growth Outlook - Sahm
Mon, 13 Oct 2025
Aberdeen Group plc Increases Position in Edwards Lifesciences Corporation $EW - MarketBeat
Sun, 12 Oct 2025
Fulcrum Capital LLC Increases Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 587 (M) |
| Shares Float | 581 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 88.1 (%) |
| Shares Short | 7,460 (K) |
| Shares Short P.Month | 10,350 (K) |
| EPS | 2.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 17.94 |
| Profit Margin | 72.9 % |
| Operating Margin | 28.1 % |
| Return on Assets (ttm) | 8.4 % |
| Return on Equity (ttm) | 15.5 % |
| Qtrly Rev. Growth | 11.8 % |
| Gross Profit (p.s.) | 7.63 |
| Sales Per Share | 9.69 |
| EBITDA (p.s.) | 2.96 |
| Qtrly Earnings Growth | -7.5 % |
| Operating Cash Flow | 795 (M) |
| Levered Free Cash Flow | 1,260 (M) |
| PE Ratio | 30.68 |
| PEG Ratio | 0 |
| Price to Book value | 4.08 |
| Price to Sales | 7.56 |
| Price to Cash Flow | 54.16 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|